| Systematic (IUPAC) name | |
|---|---|
| (3S)-2-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid | |
| Clinical data | |
| Trade names | Accupril |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a692026 |
| Pregnancy cat. | D |
| Legal status | ℞ Prescription only |
| Routes | Oral |
| Pharmacokinetic data | |
| Protein binding | 97% |
| Half-life | 2 hours |
| Identifiers | |
| CAS number | 85441-61-8 |
| ATC code | C09AA06 |
| PubChem | CID 54892 |
| DrugBank | DB00881 |
| ChemSpider | 49565 |
| UNII | RJ84Y44811 |
| KEGG | D03752 |
| ChEBI | CHEBI:8713 |
| ChEMBL | CHEMBL1592 |
| Chemical data | |
| Formula | C25H30N2O5 |
| Mol. mass | 438.516 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
|
Quinapril (marketed under the brand name Accupril by Pfizer) is an angiotensin-converting enzyme inhibitor (ACE inhibitor) used in the treatment of hypertension and congestive heart failure.
|
Contents
|
Quinapril is a prodrug. It is converted to its active metabolite, quinaprilat, in the liver.
Quinapril inhibits angiotensin converting enzyme, an enzyme which catalyses the formation of angiotensin II from its precursor, angiotensin I. Angiotensin II is a powerful vasoconstrictor and increases blood pressure through a variety of mechanisms. Due to reduced angiotensin production, plasma concentrations of aldosterone are also reduced, resulting in increased excretion of sodium in the urine and increased concentrations of potassium in the blood.
Quinapril is indicated for the treatment of high blood pressure (hypertension) and as adjunctive therapy in the management of heart failure. It may be used for the treatment of hypertension by itself or in combination with thiazide diuretics, and with diuretics and digoxin for heart failure.
Side effects of quinapril include dizziness, cough, vomiting, upset stomach, angioedema and fatigue.
|
||||||||||||||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)